Skip to main content
OpenTrials

Clinical trial condition

Lymphoproliferative Disorders

Explore clinical trials studying Lymphoproliferative Disorders. Study availability and eligibility vary by location and protocol.

10,095 public trials 2,042 recruiting studies
Refine in advanced search Browse all conditions

Lymphoproliferative Disorders trial results

Completed

A Dose-Finding Study of Folotyn® (Pralatrexate Injection) Plus CHOP With Peripheral T-Cell Lymphoma (PTCL)

NCT02594267

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Mayo Clinic Rochester, Minnesota, United States
  • Fox Chase Cancer Center Philadelphia, Pennsylvania, United States
  • MD Anderson Houston, Texas, United States
  • Seattle Cancer Care Alliance/University of Washington Seattle, Washington, United States
View Trial Details
Completed

Study of Lenalidomide Maintenance Versus Placebo in Responding Elderly Patients With DLBCL and Treated With R-CHOP

NCT01122472

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +9 more
Locations
  • Bendigo Hospital Bendigo, Australia
  • Concord Repatriation General Hospital Concord, Australia
  • Flinders Medical Centre - Repatriation General Hospital Daw Park, Australia
  • St Vincent's Hospital, Melbourne Fitzroy, Australia
View all 157 locations
View Trial Details
Completed

Brentuximab Vedotin as Consolidation Treatment in Patients With Stage I/II HL and PET Positivity After 2 Cycles of ABVD

NCT02298283

Conditions
Hemic and Lymphatic Diseases, Hodgkin Disease, Hodgkin Lymphoma, +7 more
Locations
  • CH Victor Dupouy Argenteuil, France
  • Polyclinique Bordeaux Nord Bordeaux, France
  • Centre François Baclesse Caen, France
  • CH de Chambéry Chambéry, France
View all 30 locations
View Trial Details
Completed

Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL)

NCT01553786

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +8 more
Locations
  • Université Catholique de Louvain Saint Luc Brussels, Belgium
  • Universitair Ziekenhuis Gent Ghent, Belgium
  • Université Catholique de Louvain Mont Godinne Yvoir, Belgium
  • CHU d'Amiens - Hôpital Sud Amiens, France
View all 30 locations
View Trial Details
Completed

A Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351

NCT03555955

Conditions
Acute Lymphoblastic Leukemia, Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, +18 more
Locations
  • Georgetown University Medical Center Washington D.C., District of Columbia, United States
  • Northside Hospital - Blood and Bone Marrow Transplant Group of Georgia Atlanta, Georgia, United States
  • University of Kansas Cancer Center Westwood, Kansas, United States
  • Hackensack University Medical Center Hackensack, New Jersey, United States
View all 13 locations
View Trial Details
Completed

An Extension Study to Determine the Safety and Anti-Leukemic Effects of Imatinib Mesylate in Adult Participants With Ph+ Leukemia

NCT00171249

Conditions
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Bone Marrow Diseases, +23 more
Locations
  • Dana Faber Cancer Institute Boston, Massachusetts, United States
  • New York Presbyterian Hospital New York, United States
  • Oregon Health & Sciences University Portland, Oregon, United States
  • MD Anderson Cancer Center, University of Texas Houston, Texas, United States
View Trial Details
Completed

An Extension Study to Determine the Efficacy and Safety of STI571 in Participants With Chronic Myeloid Leukemia Who Are Refractory to or Intolerant of Interferon-Alpha

NCT00171223

Conditions
Bone Marrow Diseases, Chromosome Aberrations, Chronic Disease, +20 more
Locations
  • UCLA Medical Center Los Angeles, California, United States
  • H. Lee Moffet Cancer Center & Research Institute/Univ of South Florida Tampa, Florida, United States
  • Northwestern Univ meical School/Robert H. Lurie Comprehensive Cancer Center Chicago, Illinois, United States
  • Johns Hopkins Oncology Center Baltimore, Maryland, United States
View all 28 locations
View Trial Details

Related conditions